Member Info for Kasar

Hi @potnak , do you think we will see a raise before RNS on tox study?

With big pharma looking for deals, the board should definitely use the opportunity of next week's conference to market Sar. https://www.cnbc.com/2026/06/16/biotech-deals-ipo-pharma-dealmaking-2026.html

Https://www.fiercebiotech.com/biotech/cancer-focused-parabilis-upsized-670m-ipo-breaks-new-record-biotechs

@potnak At what level are you expecting this raise to happen?

@carter19 I’ve been invested in this company for a long time now and - as many of you - I face an important loss on my initial investment. In my opinion the company needs to be in its best possible shape if and when any deal comes on the radar in order to get the maximum shareholder value. But we are not in good shape and we need things to start moving if we ever want to get there. Just my honest opinion…

The value of the science could certainly be huge, but the reality today is that we are sitting at a very low share price and a complete lack of trading volume. It’s been more than 6 months that a new broker has been appointed but I don’t see any improvement in liquidity nor shareholder value

First time to post on this board.

Looking at some of the major deals in biotech this year, the premium that is paid on top of the share price is around 40-50%. Applying that on Sar's current share price is not a nice picture. If the share doesn't increase drastically in the coming weeks/months, we will be a very cheap target for any pharma. The science is valuable, but the company isn't in my opinion. We will need a big marketing campaign if we ever want to create shareholder value.